Navigation Links
China Clean Energy Provides Business Update
Date:7/7/2009

's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the Company; the ability of the Company to expand its production capacity; the period of time for which its current liquidity will enable the Company to fund its operations; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the Company's operating results and financial condition; the Company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

    For more information, please contact:

    China Clean Energy Inc.
     Shannon Yan, CFO
     Email: shannon.yan@chinacleanenergyinc.com

    CCG Investor Relations Inc.
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Ed Job, CFA
     Phone: +1-646-213-1914
     Email: ed.job@ccgir.com

'/>"/>
SOURCE China Clean Energy Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... ... in prison for murder; guilty man kills again. , ... Rochester, NY (PRWEB) May 5, 2010 -- National Association of ... criminal investigations. A recent WHEC.com story concerns what can only be described as ...
... 4, 2010) Endoscopic radiofrequency ablation is an effective ... a fast and effective way to detect inflammatory bowel ... gastrointestinal tissue that is removed, and researchers find that ... bile duct) is more precise than surgery with fewer ...
... 4 InterMune, Inc. (Nasdaq: ITMN ) today announced that ... for the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment ... function. , , , ... letter is issued by the FDA,s Center for Drug Evaluation and Research ...
Cached Biology Technology:NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 2NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 3NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again 4Latest breakthroughs in technology expand options for diagnosing and treating disease 2Latest breakthroughs in technology expand options for diagnosing and treating disease 3Latest breakthroughs in technology expand options for diagnosing and treating disease 4Latest breakthroughs in technology expand options for diagnosing and treating disease 5Latest breakthroughs in technology expand options for diagnosing and treating disease 6Latest breakthroughs in technology expand options for diagnosing and treating disease 7Latest breakthroughs in technology expand options for diagnosing and treating disease 8Latest breakthroughs in technology expand options for diagnosing and treating disease 9Latest breakthroughs in technology expand options for diagnosing and treating disease 10Latest breakthroughs in technology expand options for diagnosing and treating disease 11InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... funding of a world-leading suite of software that allows scientists ... total 1.43M of funding has been awarded to eight components ... application process. Seven of the eight projects are ... funding the eighth. CCP4, which has contributors from ...
... have shown natural radioactivity within DNA can alter chemical ... The research, recently published in Biochimica et Biophysica ... natural radioactivity within human DNA on the atomic-scale. ... well as in every living organism across the planet, ...
... Espoo, Finland and Ebersberg, Germany, December 17th, 2013 - ... line of Eurofins Scientific and Orion Diagnostica Oy, an ... and sales of diagnostic test systems, announced that they ... Oy owns the global rights for the SIBA isothermal ...
Cached Biology News:Radioactivity muddles the alphabet of DNA 2
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: